Educating Patients on Adverse Effects Related to Talquetamab in MM

Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Extramedullary disease was the only factor that correlated with worse progression-free survival per multivariate analysis.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.

Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.